Diabetes, Vol 41, Issue 4 476-483, Copyright © 1992 by American Diabetes Association

ARTICLES

Pioglitazone increases insulin sensitivity by activating insulin receptor kinase

M Kobayashi, M Iwanishi, K Egawa and Y Shigeta
Third Department of Medicine, Shiga University of Medical Science, Ohtsu, Japan.

A new oral agent, 5-[4-(2-(5-ethyl 12-pyridyl)ethoxy]- benzoyl]-2,4-thiazolidinedione (pioglitazone), has been developed for treatment of non-insulin-dependent diabetes mellitus (NIDDM). This agent increases insulin sensitivity in vivo in genetically obese Wistar fatty rats. Administration of the agent (3 mg/kg/day) for 10 days to the rats ameliorated hyperglycemia and hyperinsulinemia, indicating that it decreased insulin resistance. To clarify the mechanism of the drug to increase insulin sensitivity, we examined insulin binding and kinase activity of insulin receptors from muscles of both untreated and treated rats. Pioglitazone treatment did not change insulin binding in Wistar fatty rats but increased insulin-stimulated autophosphorylation of insulin receptors to 78% over the level in the control but not the basal state. Kinase activity toward exogenous substrate, poly Glu4Tyr1, was also increased to 87% over the level of untreated control obese rats. In contrast, in lean rats, pioglitazone treatment did not increase autophosphorylation and kinase activity toward exogenous substrates. To further elucidate the mechanism, we incubated insulin receptors with the agent and measured kinase activity. Incubation of solubilized receptors with the agent did not increase kinase activity. However, the receptors from IM-9 cells, which were incubated with 10(-8) M pioglitazone for 7 days, showed a 46% increase over the control in insulin-stimulated autophosphorylation and kinase activity. These results suggested that pioglitazone increased insulin sensitivity in part by activating kinase of the receptors through indirect effect on insulin receptors and that the drug may have useful benefits in insulin resistance of NIDDM.
CiteULike    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				R. Basu, P. Shah, A. Basu, B. Norby, B. Dicke, V. Chandramouli, O. Cohen, B. R. Landau, and R. A. Rizza Comparison of the Effects of Pioglitazone and Metformin on Hepatic and Extra-Hepatic Insulin Action in People With Type 2 Diabetes Diabetes, January 1, 2008; 57(1): 24 - 31. [Abstract] [Full Text] [PDF]

				Y. Taniguchi, T. Ooie, N. Takahashi, T. Shinohara, M. Nakagawa, H. Yonemochi, M. Hara, H. Yoshimatsu, and T. Saikawa Pioglitazone but not glibenclamide improves cardiac expression of heat shock protein 72 and tolerance against ischemia/reperfusion injury in the heredity insulin-resistant rat. Diabetes, August 1, 2006; 55(8): 2371 - 2378. [Abstract] [Full Text] [PDF]

				J. F. Youngren, J. Paik, and R. J. Barnard Impaired insulin-receptor autophosphorylation is an early defect in fat-fed, insulin-resistant rats J Appl Physiol, November 1, 2001; 91(5): 2240 - 2247. [Abstract] [Full Text] [PDF]

				M. Iwata, T. Haruta, I. Usui, Y. Takata, A. Takano, T. Uno, J. Kawahara, E. Ueno, T. Sasaoka, O. Ishibashi, et al. Pioglitazone Ameliorates Tumor Necrosis Factor-{alpha}-Induced Insulin Resistance by a Mechanism Independent of Adipogenic Activity of Peroxisome Proliferator-Activated Receptor-{gamma} Diabetes, May 1, 2001; 50(5): 1083 - 1092. [Abstract] [Full Text]

				L. S. Liu, H. Tanaka, S. Ishii, and J. Eckel The New Antidiabetic Drug MCC-555 Acutely Sensitizes Insulin Signaling in Isolated Cardiomyocytes Endocrinology, November 1, 1998; 139(11): 4531 - 4539. [Abstract] [Full Text] [PDF]

				H. Maegawa, R. Ide, M. Hasegawa, S. Ugi, K. Egawa, M. Iwanishi, R. Kikkawa, Y. Shigeta, and A. Kashiwagi Thiazolidine Derivatives Ameliorate High Glucose-induced Insulin Resistance via the Normalization of Protein-tyrosine Phosphatase Activities J. Biol. Chem., March 31, 1995; 270(13): 7724 - 7730. [Abstract] [Full Text] [PDF]